EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy

Serena Rocchi, Beatrice Anna Zannetti, Giovanni Marconi iD, Francesco Lanza iD

Cells · 16.05.2024 · 13 (10) · 853

DOI: 10.3390/cells13100853 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 16.05.2024. Verfasst von Serena Rocchi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Unit and Romagna Metropolitan Transplant Network-Ravenna, University of Bologna, 40126 Bologna, Italy. Hauptthemen laut MEDLINE: Multiple Myeloma, Transplantation, Autologous, Immunotherapy. Die Arbeit wurde bisher 30-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AIL Ravenna (Associazione Italiana Leucemie).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Upfront high-dose therapy with melphalan (HDM) followed by autologous stem cell transplantation (ASCT) has established itself as a core treatment for newly diagnosed multiple myeloma (NDMM) patients in the past 30 years. Induction therapy, HDM-ASCT, and subsequent consolidation and maintenance therapy comprise the current fundamental framework for MM treatment. The introduction of anti-CD38 monoclonal antibodies such as daratumumab and isatuximab has changed the treatment paradigm for transplant-eligible NDMM patients in that quadruplets have become the new standard induction therapy. The treatment landscape of MM is undergoing a transformative shift with the introduction of potent new immunotherapies, such as chimeric antigen receptor (CAR)-T cells and bispecific antibodies (BsAbs), which are currently used in the relapsed/refractory setting (RRMM) and are already being tested in the NDMM. This review will focus on the incorporation of immunotherapy in the treatment scenario of NDMM patients eligible for ASCT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaTransplantation, AutologousImmunotherapyHumansHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

bispecific antibodiesimmunotherapymultiple myelomastem cell transplantation

Autor:innen und Institutionen

  • Hematology Unit and Romagna Metropolitan Transplant Network-Ravenna, University of Bologna, 40126 Bologna, Italy.

ORCID-Profile: Giovanni Marconi, Francesco Lanza

Förderung

  • AIL Ravenna (Associazione Italiana Leucemie)

Zitieren

APA

Rocchi, S., Zannetti, B. A., Marconi, G., & Lanza, F. (2024). Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy. Cells, 13(10), 853. https://doi.org/10.3390/cells13100853

Vancouver

Rocchi S, Zannetti BA, Marconi G, Lanza F. Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy. Cells. 2024;13(10):853. doi:10.3390/cells13100853

BibTeX
@article{Rocchi2024,
  author = {Rocchi, Serena and Zannetti, Beatrice Anna and Marconi, Giovanni and Lanza, Francesco},
  title = {Multiple Myeloma: The Role of Autologous Stem Cell Transplantation in the Era of Immunotherapy},
  journal = {Cells},
  year = {2024},
  volume = {13},
  number = {10},
  pages = {853},
  doi = {10.3390/cells13100853}
}
Kostenlos starten →